Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: The first case report from Indonesia

Clinical Rheumatology

Volumn 28, Issue SUPPL. 1, 2009, Pages

  Mardjuadi, A ^a   Soedirman, M ^a   Utoyo, Buddy ^a   Rasker, J J ^b  

^a National Development University   (Indonesia)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Rituximab; Severe systemic lupus erythematosus

Indexed keywords

ALBUMIN; ANTINUCLEAR ANTIBODY; CHINESE DRUG; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; GLOBULIN; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ALBUMIN BLOOD LEVEL; ARTHRITIS; ARTICLE; BODY RASH; CACHEXIA; CASE REPORT; CHINESE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENERALIZED EDEMA; HEADACHE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDONESIA; LABORATORY DIAGNOSIS; LEUKOCYTE COUNT; MOON FACE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; WEIGHT REDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INDONESIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDNISOLONE; REMISSION INDUCTION;

EID: 67349281550     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1069-8     Document Type: Article

References (19)

1. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus, mechanisms of disease. New Engl J Med 358:929-939
2. Golbus J, McCune WJ (1994) Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am 20:223-242
3. Tieng AT, Peeva E (2008) B-cell directed therapies in systemic lupus erythematosus. Semin Arhritis Rheum 38:218-227
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arhtritis Rheum 25:1271-1277
5. Gottenberg J-E, Guillevin L, Lambotte O et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:923-920
6. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF (2007) Histopathologic and clinical outcome of Rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56:2263-2272
7. Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, Fakhouri F (2008) Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 52:346-352
8. Leandro MJ, Cambridge G, Edward JC, Ehrenstein MR, Isenberg DA (2005) B cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:2542-2545
9. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA (2006) Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 65:942-945
10. Sfikakis PP, Boletis JN, Tsokos GC (2005) Rituximab anti-B-cell therapy in systemic lupus Erythematosus: Pointing to the future. Curr Opin Rheumatol 27:550-557
11. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson W, Klareskog L, van Vollenhoven RF (2008) Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes and predictors of response. Ann Rheum Dis 67:330-334
12. Risselada AP, Kallenberg CGM (2006) Therapy resistant lupus skin disease successfully treated with rituximab. Rheumatology 45:925-926 features in systemic lupus erythematosus: Analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33:227-230
13. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Loly P (2006) Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 233:53-55
14. Mo N, Collins P, Rayment P, Nash J (2007) The use of rituximab in a case of SLE complicated by TTP and refractory ITP. l EULAR: AB 0434
15. Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundquist AC, Tarkowski A, Bokarewa M (2008) Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35:826-833
16. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, Rousset H, Salles G, Broussolle C, Seve P (2006) Treatment of isolated severe immune hemolytic anemia associated with systemic lupus erythematosus: 26 cases. Lupus 25:223-232
17. Perrotta S, Locatelli F, La Manna A, Cennamo L, de Stefano P, Nobili B (2002) Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Brit J Haematol 226:465-467
18. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:2862-2875
19. Calabrese LH, Molloy ES, Huang DR, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56:2226-2228